Search / Trial NCT00002244

A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients With Late-Stage HIV Disease

Launched by OXO CHEMIE · Aug 30, 2001

Trial Information

Current as of December 07, 2024

Completed

Keywords

Placebos Infusions, Intravenous Quality Of Life Anti Hiv Agents Tetrachlorodecaoxide

ClinConnect Summary

Patients are randomized to 1 of 2 treatment groups to receive 4 IV treatment cycles of either WF10 or control (physiological saline solution). Patients are monitored throughout the study for: a) clinical progression; b) number, duration, and cause of hospitalizations; c) quality of life; and d) density of CD38 antigen on CD8+ T cells. Patients receive treatment for 11 weeks but will continue to be followed for a maximum of 96 weeks. During the follow-up period, patients are evaluated initially at Week 18, then at Weeks 24, 36, and 48. If the study is continued beyond Week 48, follow-up visi...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Patients may be eligible for this study if they:
  • Are HIV-positive.
  • Have a CD4 cell count of less than 50 cells/mm3 within 14 days prior to study entry.
  • Are at least 18 years old.
  • Have received anti-HIV drugs at some time in the past.
  • Agree to practice abstinence or use effective methods of birth control, including the pill, during the study.
  • Exclusion Criteria
  • Patients will not be eligible for this study if they:
  • Are being treated for any form of cancer within 30 days of study entry.
  • Have ever received an HIV vaccine.
  • Have received steroids within 30 days prior to study entry. (Note: Testosterone is allowed.)
  • Have received certain medications, including anti-HIV treatments that are not approved by the FDA.
  • Have participated in another WF10 study.
  • Have an illness or any condition that might exclude them from this study.
  • Are pregnant or breast-feeding.
  • Abuse drugs or medications.
  • Received a blood transfusion within 45 days prior to study entry.

About Oxo Chemie

Oxo Chemie is a leading sponsor in the pharmaceutical and biotechnology sectors, specializing in the development and commercialization of innovative therapeutic solutions. With a strong commitment to advancing healthcare, Oxo Chemie focuses on conducting rigorous clinical trials to evaluate the safety and efficacy of its novel compounds. The company leverages cutting-edge research methodologies and collaborates with renowned research institutions to ensure high standards of clinical excellence. Driven by a passion for improving patient outcomes, Oxo Chemie is dedicated to addressing unmet medical needs through its robust pipeline of drug candidates.

Locations

Birmingham, Alabama, United States

Chicago, Illinois, United States

Atlanta, Georgia, United States

Oakland, California, United States

Miami, Florida, United States

San Francisco, California, United States

Washington, District Of Columbia, United States

Halifax, Nova Scotia, Canada

Toronto, Ontario, Canada

San Francisco, California, United States

Iowa City, Iowa, United States

Seattle, Washington, United States

Hampton, Virginia, United States

Detroit, Michigan, United States

Montreal, Quebec, Canada

Tampa, Florida, United States

Ottawa, Ontario, Canada

Boston, Massachusetts, United States

Los Angeles, California, United States

Tampa, Florida, United States

Honolulu, Hawaii, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

St. Paul, Minnesota, United States

Kansas City, Missouri, United States

Newark, New Jersey, United States

Albuquerque, New Mexico, United States

Tulsa, Oklahoma, United States

Philadelphia, Pennsylvania, United States

Charleston, South Carolina, United States

Columbia, South Carolina, United States

Vancouver, British Columbia, Canada

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials